Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in <scp>Triple‐Negative</scp> Breast Cancer
Benjamin C. Musall(Henry Ford Health System), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Marion E. Scoggins(The University of Texas MD Anderson Cancer Center), Lumarie Santiago(Nektar Therapeutics (United States)), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Rania M. Mohamed(The University of Texas MD Anderson Cancer Center), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Jong Bum Son(The University of Texas MD Anderson Cancer Center), Jia Sun(Nanjing University of Chinese Medicine), Clinton Yam(The University of Texas MD Anderson Cancer Center), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Tanya W. Moseley(The University of Texas MD Anderson Cancer Center), Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Nabil Elshafeey(The University of Texas MD Anderson Cancer Center), Vicente Valero(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Medine Böge(The University of Texas MD Anderson Cancer Center), Shu Zhang(Healthwise), Jingfei Ma(The University of Texas MD Anderson Cancer Center), Mark D. Pagel(University of Wisconsin–Madison), Hagar S. Mahmoud(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Abeer H. Abdelhafez(The University of Texas MD Anderson Cancer Center), Ken‐Pin Hwang(The University of Texas MD Anderson Cancer Center), Gary J. Whitman(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795